PURPOSE: The purpose of this study is to provide information about sexual function (SF) after three-dimensional conformal radiotherapy (3D-CRT) for prostate cancer while taking important factors into account that influence SF. METHODS AND MATERIALS: Between June 1997 and February 2003, a total of 268 patients from a randomized dose-escalation trial comparing 68 Gy and 78 Gy agreed to participate in an additional part of the trial that evaluated SF. RESULTS: At baseline 28% of patients had erectile dysfunction (ED). After 1 year, 27% of the pretreatment potent patients had developed ED. After 2 years this percentage had increased to 36%. After 3 years it almost stabilized at 38%. Satisfaction with sexual life was significantly correlated with ED. After 2 years one third of the pre-treatment potent patients still had considerable to very much sexual desire and found sex (very) important. No significant differences were found between the two dose-arms. Potency aids were used on a regular base by 14% of the patients. CONCLUSION: By taking adjuvant hormonal therapy (HT), HT during follow-up and potency aids into account, we found a lower percentage of ED after 3D-CRT than reported in previous prospective studies. A large group of patients still had sexual desire, considered sex important and 14% used potency aids after 3D-CRT.
RCT Entities:
PURPOSE: The purpose of this study is to provide information about sexual function (SF) after three-dimensional conformal radiotherapy (3D-CRT) for prostate cancer while taking important factors into account that influence SF. METHODS AND MATERIALS: Between June 1997 and February 2003, a total of 268 patients from a randomized dose-escalation trial comparing 68 Gy and 78 Gy agreed to participate in an additional part of the trial that evaluated SF. RESULTS: At baseline 28% of patients had erectile dysfunction (ED). After 1 year, 27% of the pretreatment potent patients had developed ED. After 2 years this percentage had increased to 36%. After 3 years it almost stabilized at 38%. Satisfaction with sexual life was significantly correlated with ED. After 2 years one third of the pre-treatment potent patients still had considerable to very much sexual desire and found sex (very) important. No significant differences were found between the two dose-arms. Potency aids were used on a regular base by 14% of the patients. CONCLUSION: By taking adjuvant hormonal therapy (HT), HT during follow-up and potency aids into account, we found a lower percentage of ED after 3D-CRT than reported in previous prospective studies. A large group of patients still had sexual desire, considered sex important and 14% used potency aids after 3D-CRT.
Authors: A Magli; M Giangreco; M Crespi; A Negri; T Ceschia; G De Giorgi; F Titone; G Parisi; S Fongione Journal: Strahlenther Onkol Date: 2012-09-29 Impact factor: 3.621
Authors: Deborah Watkins Bruner; Jennifer L James; Charlene J Bryan; Thomas M Pisansky; Marvin Rotman; Thomas Corbett; Joycelyn Speight; Roger Byhardt; Howard Sandler; Søren Bentzen; Lisa Kachnic; Lawrence Berk Journal: J Sex Med Date: 2011-01-14 Impact factor: 3.802
Authors: Mack Roach; Jiho Nam; Giovanna Gagliardi; Issam El Naqa; Joseph O Deasy; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Michael Pinkawa; Marc D Piroth; Richard Holy; Victoria Djukic; Jens Klotz; Barbara Krenkel; Michael J Eble Journal: Strahlenther Onkol Date: 2011-07-25 Impact factor: 3.621
Authors: N Pervez; A V Krauze; D Yee; M Parliament; A Mihai; S Ghosh; K Joseph; A Murtha; J Amanie; M Kamal; R Pearcey Journal: Curr Oncol Date: 2012-06 Impact factor: 3.677
Authors: L J Hanisch; C J Bryan; J L James; T M Pisansky; T B Corbett; M B Parliament; C E Stewart; A C Hartford; H Sandler; L B Berk; L Kachnic; D W Bruner Journal: Support Care Cancer Date: 2012-02-22 Impact factor: 3.603